Targeted therapies for CAFs in pancreatic cancer include focal adhesion kinase (FAK), neuregulin 1 (NRG1), LRRC15+ CAFs, etc., The FAK inhibitor suppressed tumor cells and CAFs in a mouse model (Stokes et al., 2011; Kanteti et al., 2018). Here, NRG1 is linked to familial pancreatic carcinoma.